Evidence map›Paper›PMID 36505864›Full record

ArticleFrontiers in oncology2022

Thibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, Rania El Botty, Laura Courtois, Sophie Vacher, Elisabetta Marangoni, Fariba Nemati, Sergio Roman-Roman, Homa Adle-Biassette and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Thibault PasseriLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, Paris, France.
Ahmed DahmaniLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, Paris, France.
Julien Masliah-PlanchonDepartment of Genetics, Institut Curie, University of Paris Saclay, Paris, France.
Rania El BottyLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, Paris, France.
Laura CourtoisDepartment of Genetics, Institut Curie, University of Paris Saclay, Paris, France.
Sophie VacherDepartment of Genetics, Institut Curie, University of Paris Saclay, Paris, France.
Elisabetta MarangoniLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, Paris, France.
Fariba NematiLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, Paris, France.
Sergio Roman-RomanDepartment of Translational Research, Institut Curie, University of Paris Saclay, Paris, France.
Homa Adle-BiassetteDepartment of Pathology, Lariboisière Hospital, Assistance Publique des Hôpitaux de Paris, University of Paris, Paris, France.
Hamid MammarDepartment of Radiotherapy - Proton Therapy Center, Institut Curie, Paris-Saclay University, Orsay, France.
Sébastien FroelichDepartment of Neurosurgery, Lariboisière Hospital, Assistance Publique des Hôpitaux de Paris, University of Paris, Paris, France.
Ivan BiècheDepartment of Genetics, Institut Curie, University of Paris Saclay, Paris, France.
Didier DecaudinLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, Paris, France.
Université Paris-Saclay · FRInstitut Curie · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene Methods: From our chordoma xenograft panel, we selected three models, two of them harboring a homozygous deletion of Results: For palbociclib, we observed a significant tumor response for one of two models harboring the deletion of Conclusion: CDK4/6 inhibition appears as a promising strategy to manage advanced chordomas harboring a loss of

Indexed as

CDK4/6 inhibitorCDKN2A/2B deletionchordoma patient’s derived xenograftpalbocicibPLK1 inhibitorvolasertib

Identifiers

PMID36505864
PMCPMC9732546
OpenAlexW4310037161

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.